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The CXCL12-CXCR4 axis is involved in many physiological processes. Zirafi et al. show that an endogenous fragment of human serum albumin (LVRYTKKVPQVSTPTL) efficiently suppresses CXCR4 signaling and inhibits infection by CXCR4-tropic HIV-1 strains.
INTRODUCTION
CXC chemokine receptor 4 (CXCR4) is a G protein-coupled receptor (GPCR) that is expressed on multiple cells, including those of the hematopoietic and CNSs (Feng et al., 1996; Zou et al., 1998) . Activation of CXCR4 by its only known chemokine ligand, stromal-cell-derived factor-1 (SDF-1 or CXCL12) (Bleul et al., 1996; Oberlin et al., 1996) , governs important physiological processes, such as organogenesis, angiogenesis, migration of immune cells, and renal function, as well as retention of hematopoietic stem cells (HSCs) in the bone marrow (Petit et al., 2002; Nie et al., 2004; Chen et al., 2014) . Deregulation of CXCR4/ CXCL12 signaling is associated with numerous pathological conditions, including various types of cancers, chronic inflammatory diseases, cardiovascular diseases, and immunodeficiencies (Gonzalo et al., 2000; Nanki et al., 2000; Mü ller et al., far, however, only a single antagonist (plerixafor, AMD3100) has been approved for stem cell mobilization in patients who do not respond to chemotherapy or granulocyte colony-stimulating factor (G-CSF) (Devine et al., 2008) .
To identify unknown endogenous CXCR4 ligands, we generated a peptide library derived from $10,000 l of hemofiltrate (HF) . This blood ultrafiltrate is obtained from dialysis centers and contains essentially the entire circulating blood peptidome with millions of compounds (Schulz-Knappe et al., 1997; Mü nch et al., 2014) . Previously, we used this resource to discover an HIV-1 entry inhibitor that targets the viral gp41 fusion peptide (Mü nch et al., 2007b) , and demonstrated that an optimized derivative thereof suppressed HIV-1 replication in humans (Forssmann et al., 2010) . Furthermore, we identified an agonist of CCR5 (Detheux et al., 2000; Mü nch et al., 2002; Forssmann et al., 2010) , the second main coreceptor of HIV-1 entry (Deng et al., 1996; Dragic et al., 1996) . Here, we screened an HF-derived peptide library for inhibitors of CXCR4-tropic (X4) HIV-1 and identified an endogenous antagonist of CXCR4 that is generated by limited proteolysis of serum albumin, the most abundant protein in human plasma.
RESULTS

Isolation of an Endogenous Inhibitor of X4 HIV-1
The screening of 350 fractions of an HF-derived peptide library identified three adjacent peptide fractions that blocked X4-HIV-1 ( Figure 1A ). Further rounds of chromatographic separation and X4-HIV-1 inhibition assays ( Figure S1 ) yielded a peptide of 1,830 Da with the amino acid sequence LVRYTKKVPQVSTPTL, which corresponds to residues 408-423 of human serum albumin (HSA) ( Figure 1A ). HSA is the most abundant protein in the blood, with reference concentrations between 34 and 54 g/l, and is also abundant in the extravascular space (Peters, 1996) . The isolated peptide was previously detected by mass spectrometry in HF and the urine of patients with graft-versus-host and kidney disease (Kaiser et al., 2004; Chalmers et al., 2005; Wittke et al., 2005; Aristoteli et al., 2007) , but its biological function remained unknown. (C) Synthetic EPI-X4 inhibits X4, but not R5, HIV-1. TZM-bl cells were infected with the indicated HIV-1 NL4-3 recombinants in the absence or presence of EPI-X4 (100 mg/ml), and infection rates were determined 3 days later. Values represent the mean ± SD of triplicate infections (D) EPI-X4 blocks HIV-1 infection by interacting with the cell. X4 HIV-1 was pretreated with the peptide prior to infection or cells were treated with EPI-X4 and subsequently infected with HIV-1 (cells). Values represent the mean of triplicate infections. (E) EPI-X4 is not cytotoxic. Phytohemagglutinin/IL-2-stimulated peripheral blood mononuclear cells or TZM-bl cells were incubated with the indicated concentrations of EPI-X4. After 3 days, cell viability was measured by quantifying the cell-associated ATP levels. Values represent the mean ± SD of triplicate cultures. (F) Infection of TZM-bl cells with X4 and R5 HIV-1 in the presence of full-length HSA. Values represent the mean of triplicate infections. See also Figure S1 and Tables S1 and S2.
The synthetic peptide inhibited X4-HIV-1 infection with a mean 50% inhibitory concentration (IC 50 ) of 15.8 mg/ml (corresponding to 8.6 mM) ( Figure 1B ; Table S1 ), but had no effect on CCR5-(R5) tropic HIV-1 strains ( Figures 1B and 1C) . Treatment of target cells, but not of virions, prevented HIV-1 infection (Figure 1D) , suggesting that the peptide, named EPI-X4 (endogenous peptide inhibitor of CXCR4), targets the CXCR4 coreceptor of HIV-1 entry. EPI-X4 is not cytotoxic ( Figure 1E ; Table S2 ) and its albumin precursor exhibited no antiviral effect ( Figure 1F ). Thus, a naturally occurring fragment of the most abundant protein in human plasma specifically inhibits X4 HIV-1 infection.
EPI-X4 Is a Natural CXCR4 Antagonist
We next determined whether EPI-X4 interacts directly with CXCR4. EPI-X4 competed for CXCL12 binding to CXCR4 with an IC 50 of 8.6 ± 3.1 mM, corresponding to a dissociation constant (K i value) of 3 ± 1 mM (Figure 2A ). Thus, active concentrations of this peptide can be generated by proteolytic cleavage of $1% of its albumin precursor. The peptide also interfered with the binding of the monoclonal antibody 12G5, which interacts with the second extracellular loop of CXCR4, but had no effect on 1D9, which targets the N terminus ( Figure S2A ). EPI-X4 did not induce Ca 2+ mobilization ( Figure S2B ) and has thus no CXCR4 agonistic activity. However, EPI-X4 inhibited CXCL12-induced Ca 2+ mobilization (Figures 2B and S2B) and receptor internalization (Figures S2C and S2D) . These effects were highly specific since EPI-X4 did not affect ligand-induced signaling via any other GPCR investigated (Figures S2B and S2E) . Furthermore, EPI-X4 did not interfere with CXCL12-induced internalization of CXCR7 ( Figure S2F ), the alternative receptor for CXCL12 (Burns et al., 2006) , and suppressed basal CXCR4 signaling (Figure S2G) . Next, we examined whether EPI-X4 affects cellular migration along a CXCL12 gradient. We found that EPI-X4 inhibits CXCL12-induced migration of leukemia cells ( Figure 2C ) and human CD34 + hematopoietic cells ( Figure 2D ), as well as prostate tumor cell invasion ( Figure 2E ). Thus, EPI-X4 is an endogenous antagonist and inverse agonist of CXCR4 that exerts anti-invasive and anti-metastatic effects.
EPI-X4 Modulates CXCR4 Signaling In Vivo
Expression of CXCL12 by bone marrow stromal cells provides a retention signal for CXCR4-expressing HSCs and neutrophils in the bone marrow. In agreement with the antagonistic activity of EPI-X4 described above, a single intraperitoneal injection of this peptide into mice resulted in marked mobilization of HSCs ( Figure 3A ) and neutrophils ( Figure 3B ) into the periphery. Notably, the mobilized cells included transplantable cells, as they engrafted lethally irradiated hosts ( Figure 3C ). Given that CXCR4 plays a key role in inflammation, we also examined whether EPI-X4 exerts anti-inflammatory effects in a mouse model of acute allergic airway hypereosinophilia (Reber et al., 2012) . Administration of EPI-X4 prior to allergen (ovalbumin [OVA] ) challenge reduced CXCR4-dependent infiltration of eosinophils, neutrophils, and lymphocytes into the airways, whereas a derivative lacking the N-terminal L (Table S1 ) was inactive (Figure 3D) . Thus, EPI-X4 mobilizes HSCs and exerts anti-inflammatory effects in vivo.
EPI-X4 Is Evolutionarily Conserved
A physiologically relevant CXCR4 antagonist should be evolutionarily conserved. Indeed, alignment of albumin sequences from different mammalian species revealed variations at only three amino acid positions of EPI-X4: L1I/A, K6R/Q, and V8A/L ( Figure 4A ). Quantitative analyses confirmed that the conservation score of the region corresponding to EPI-X4 and its flanking residues (that may allow its proteolytic generation) is significantly greater (0.98) than that of the remainder of the albumin molecule (0.87; p = 0.006; Figures 4B and 4C ). Importantly, substitution of the N-terminal L by I, which was observed in several species ( Figure 4A ), increased the activity of human EPI-X4 (Table S1) . Notably, both human-and murine-derived EPI-X4 efficiently suppressed CXCL12-induced migration of mouse cells ( Figure 4D ), suggesting that this endogenous CXCR4 antagonist is functionally conserved from mice to humans.
Structure and Optimization of EPI-X4
To better understand the mechanism underlying EPI-X4 function, we used NMR to solve its 3D structure ( Figure 5A ; Table S3 ). Interactions among L1, Y4, and P9 cause the backbone of the L1-P9 stretch to adopt a ring-like structure with a ''tail'' formed by residues V11-L16 ( Figure 5B ). The ring displays one highly positively charged and one strongly hydrophobic surface ( Figure 5C ). Computational modeling with the published CXCR4 structure (Wu et al., 2010) suggests that the positively charged face of the ring of EPI-X4 interacts with the negatively charged extracellular face of CXCR4 similarly to CXCL12 and the V3 loop of the HIV-1 gp120 exterior envelope glycoprotein ( Figure S3) . Indeed, mutational analyses demonstrated that truncations of the C-terminal tail were tolerated ( Figure 6A ; Table S1 ), whereas N-terminal truncations that eliminated the ring structure resulted in a loss of activity ( Figure 6B ). Furthermore, substitutions of L1I ( Figure 6C ) and Y4W or T5S ( Figure 6D ) increased the antiviral activity, and combinations of these mutations ( Figure 6E ), including dimerization ( Figure 6F ), resulted in EPI-X4 derivatives with IC 50 values in the nanomolar range (Table S1 ). The antiviral activity of optimized EPI-X4 derivatives correlated with their potency in inhibiting T cell migration ( Figure S4A ). The optimized dimeric WSC02x2 derivative also displayed strongly increased serum stability ( Figure S4B ), and suppressed CXCL12-induced actin polymerization in T cells ( Figure S4C ) and HSC migration ( Figure S4D ) more effectively than the parental peptide. Thus, these analyses allowed the generation of EPI-X4 derivatives with substantially increased stability and potency.
Half-Life of EPI-X4
For fast and effective regulation of CXCR4, the activity of EPI-X4 should be tightly regulated. In agreement with this requirement, the half-life of EPI-X4 spiked into plasma from healthy human individuals was only $17 min ( Figure 7A ), as determined by an EPI-X4-specific sandwich ELISA (Mohr et al., 2015) . Degradation and functional inactivation in plasma were blocked by L-leucinethiol (LT), an inhibitor of leucyl aminopeptidases (LAPs; Figure 7B) , a group of cell-maintenance enzymes that play critical roles in the turnover of bioactive peptides and immune function (Matsui et al., 2006) . These results underline the critical role of the N-terminal L-residue in the antagonistic activity of EPI-X4.
Generation of EPI-X4 from Albumin EPI-X4 is accessible at the surface of albumin and flanked by putative protease cleavage sites ( Figure S5A ). We found that cathepsins D and E efficiently generated EPI-X4 from albumin under acidic conditions ( Figure 7C ). These aspartic proteases are major components of the endo-and lysosomal protein degradation pathway of virtually all cells (Zaidi and Kalbacher, 2008; Sun et al., 2013) and are released by exocytosis from immune cells during inflammatory processes (Yamamoto et al., 2012; Appelqvist et al., 2013) . Indeed, immature dendritic cells and neutrophils supplemented with albumin produced EPI-X4 ( Figure S6 ). Cathepsin D also circulates in an inactive form in human blood and is activated under acidic pH conditions (Tandon et al., 1990) . Remarkably, we found that acidification of human plasma, which usually does not contain detectable amounts of EPI-X4 (Mohr et al., 2015) , resulted in the effective de novo generation of biologically active concentrations of the CXCR4 antagonist ( Figure 7D ), and this process was blocked by pepstatin A, an inhibitor of aspartic proteases ( Figure 7E ). In agreement with a conserved regulatory role in CXCR4 signaling, EPI-X4 was also detectable in acidified sera from rhesus macaques ( Figure S5B ) and mice ( Figure S5C ). Notably, we detected higher levels of EPI-X4 in acidified sera of HIV-infected individuals with rapid disease progression (36.7 ± 9.0 mg/ml, n = 37) or chronic disease (27.9 ± 8.5 mg/ml, n = 56) than in sera obtained from elite controllers (6.3 ± 6.2 mg/ml, n = 9; Figure 7F ). Thus, sera from patients with high levels of inflammation have an increased potential to generate EPI-X4. Altogether, these results suggest that EPI-X4 is effectively generated by acidic proteases present at sites of infection or inflammation, but is rapidly inactivated by serum LAP in neutral, non-inflammatory environments. Table S1 .
Urinary EPI-X4 Is a Marker for Chronic Kidney Disease To determine whether EPI-X4 is induced under inflammatory conditions, we measured its urinary levels in patients with renal failure and in healthy controls (without prior acidification of the urine samples). High levels of EPI-X4 (1.73 ± 0.87 mg/ml, n = 12) were detected in the urine of patients with macroalbuminuria. In contrast, the levels were low in individuals with microalbuminuria (0.22 ± 0.10 mg/ml, n = 39) and essentially absent in those with no albuminuria (0.024 ± 0.004 mg/ml, n = 277; Figure 7G ). Furthermore, the urinary levels of EPI-X4 were inversely correlated with the glomerular filtration rate (GFR) in these patients (r = À0.131, p = 0.026). Notably, we never observed that EPI-X4 was produced after urination, and its concentrations remained stable in urine over several days (Mohr et al., 2015) . Thus, EPI-X4 is likely generated by the kidneys in vivo and its urinary levels may represent a prognostic marker for renal inflammation and chronic kidney disease. Table S1 .
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DISCUSSION
In the present study, we identified EPI-X4 as an evolutionarily conserved endogenous antagonist of CXCR4 that may play important roles in physiological processes and diseases. EPI-X4 is an endogenous antagonist of a chemokine receptor that is generated from a highly abundant protein with unrelated function. The precursor, serum albumin, is ubiquitously present in intra-and extravascular compartments of the entire body with reference concentrations between 34 and 54 mg/ml (Peters, 1996) . The EPI-X4-generating proteases are also available anywhere in human plasma. Thus, the ''prerequisites'' for rapid generation of the CXCR4 antagonist are essentially provided everywhere in the human body.
Production of EPI-X4 is likely induced by local extracellular acidification, which represents a hallmark of inflammatory tissues (Mogi et al., 2009; Dong et al., 2013; Okajima, 2013) and is emerging as a key regulatory concept for innate immunity (Rajamä ki et al., 2013) . Acidification results in the activation of aspartic proteases, such as cathepsins D and E, that may be secreted by lysosomal exocytosis during immune responses (Rodríguez et al., 1997; Stinchcombe et al., 2000) or via specialized secretory granules of immune cells (Levy et al., 1989; Burns et al., 2006; Yamamoto et al., 2012) . Thus, EPI-X4 most likely is specifically generated at sites of infection and inflammation, and may help to trap immune cells at their places of action by preventing CXCR4-dependent migration. In addition, EPI-X4 may also be generated intracellular by lysosomal degradation of albumin (Benes et al., 2008) and subsequent release into the extracellular space after apoptosis or pyroptosis. Acidic pH values and high levels of cathepsin D are also characteristic of malignant tumors (Liaudet-Coopman et al., 2006; Benes et al., 2008; Estrella et al., 2013; Kato et al., 2013) . Since EPI-X4 suppresses the migration of tumor cells, it will be of high interest to determine whether this endogenous CXCR4 antagonist may affect cancer development and tumor metastasis in vivo.
Our results support previous hypotheses that urinary EPI-X4 might serve as an early marker for renal damage, as the appearance of this peptide seems to be affected by initial changes in proteolytic activity associated with inflammatory processes at the onset of renal disease (Chalmers et al., 2005; Wittke et al., 2005) . The CXCR4/CXCL12 signaling pair preserves microvascular integrity and renal function in patients with chronic kidney disease (Chen et al., 2014) , and elevated levels of CXCL12 predict incident of myocardial infarction and death in these patients (Mehta et al., 2014) . Thus, increased endogenous levels of EPI-X4 may represent a specific response against overshooting CXCR4 signaling. Moreover, these observations suggest that EPI-X4 or its improved derivatives have therapeutic potential in chronic kidney disease and associated disorders.
EPI-X4 was initially identified as an inhibitor of X4 HIV-1. It is tempting to speculate that the emergence of X4 HIV-1 strains during the chronic phase of infection (Connor et al., 1997) might correlate with declining concentrations of EPI-X4. However, EPI-X4 could not be detected in non-acidified plasma samples derived from HIV-1-infected individuals with late-stage disease, arguing against an essential role of EPI-X4 in the coreceptor switch. Whether or not occupancy of CXCR4 by EPI-X4 represents the long-sought ''gate-keeping'' mechanism that restricts sexual or perinatal transmission of X4 HIV-1 is being addressed in ongoing studies.
The finding that EPI-X4 also reduces the basal signaling activity of CXCR4 and thus acts as an inverse agonist may have important implications because it suggests that CXCR4 activity is not solely dependent on CXCL12. CXCR4 is of significant interest as a drug target (Peled et al., 2012; Cojoc et al., 2013) , and EPI-X4 has interesting properties for clinical development because it mobilizes stem cells and prevents inflammatory cell infiltration in vivo. Moreover, it is not immunogenic or cytotoxic, whereas plerixafor, the only approved CXCR4 antagonist (Devine et al., 2008) , affects mitochondria function (Table S2) . Furthermore, EPI-X4 is functionally distinct from plerixafor because it does not bind to CXCR7 and also acts as an inverse agonist of CXCR4. Many clinically used GPCR antagonists display inverse agonist activity (Kenakin, 2004) . Thus, EPI-X4 and its derivatives may be useful for the treatment of diseases associated with excessive activity of CXCR4, such as chronic inflammatory disorders and WHIM syndrome, a congenital immunodeficiency associated with increased susceptibility to human papilloma virus infection (Hernandez et al., 2003) .
Our identification of an endogenous antagonist of CXCR4 signaling opens up exciting possibilities for future research. The proteolytic generation of a bioactive peptide from an abundant precursor protein represents a novel concept for the regulation of GPCRs, which are the largest and most diverse group of membrane receptors in eukaryotes and targets of almost half of all modern drugs (Lappano and Maggiolini, 2011) . Our data show that this regulation of CXCR4 activity is conserved from mice to humans, and it will be interesting to determine whether other GPCRs are regulated by similar means.
EXPERIMENTAL PROCEDURES Generation and Screening of HF Libraries
Fractions of an HF-derived peptide library (Schulz-Knappe et al., 1997) were tested for their ability to block X4 HIV-1 NL4-3 infection in P4-CCR5 cells See also Figure S3 and Table S3 . (Mü nch et al., 2007b) . The cells were grown in DMEM supplemented with 10% fetal calf serum (FCS) and 1 mg/ml puromycin (GIBCO BRL). Cells were seeded in flat-bottomed 96-well dishes, cultured overnight, and incubated with fractions for 2 hr before they were infected with virus containing 20 ng of p24 antigen in a total volume of 100 ml of medium. Three days after infection, the cells were lysed and infection rates were determined using the one-step Tropix Gal-Screen Kit as recommended by the manufacturer. Peptides were synthesized and the effects on HIV-1 infection in TZM-bl cells were determined as previously described (Mü nch et al., 2007a (Mü nch et al., , 2007b . Infection rates were determined after 3 days using the one-step Tropix Gal-Screen Kit.
Real-Time Fluorescence Monitoring of Ligand-Receptor Interactions
The human chemokines CXCL12 and CXCL12-TexasRed were kindly provided by Dr. F. Baleux (Institut Pasteur, Paris, France). The synthesized T134 peptide (Tamamura et al., 1998) , a small analog of T22 (a peptide derived from the polyphemusin II), was purchased from Genecust. Experiments were performed using HEK293 cells stably expressing EGFP-hCXCR4, suspended in HEPES-BSA buffer. Time-based recordings of the fluorescence emitted at 510 nm (excitation at 470 nm) were performed at 21 C with a spectrofluorometer and sampled every 0.3 s. Fluorescence binding measurements were initiated at 30 s by adding 100 nM of CXCL12-TR. For competition experiments, EGFP-CXCR4-expressing cells were preincubated for 10 min in the absence or presence of various concentrations of unlabeled T134 or EPI-X4. Subsequently, CXCL12-TR (100 nM) was added, and fluorescence was recorded until equilibrium was reached (300 s). Data were analyzed using KaleidaGraph 3.08 software (Synergy Software).
Intracellular Ca 2+ Release Measurement
Measurements of intracellular Ca 2+ release were carried out as previously described (Tamamura et al., 1998; Hachet-Haas et al., 2008) using indo-1 acetoxymethyl ester as the calcium probe. HEK293 cells expressing CXCR4, CCR5, or CXCR1 were preincubated for 30 min with 100 mM of EPI-X4 or buffer. Calcium release was induced by addition of their natural ligands (CXCL12, 10 nM; CCL5, 50 nM; and CXCL8, 50 nM). Cellular responses were recorded at 37 C in a 1 ml stirring cuvette with excitation set at 355 nm and emission set at 405 and 475 nm using a spectrofluorometer. Data were analyzed using KaleidaGraph 3.08 software (Synergy Software). The human chemokines CCL5, CXCL8, and CXCL11 were purchased from Clinisciences SAS. See also Figure S4 and Table S1 .
Effect of EPI-X4 and Derivatives on Cell Migration
Cell Reports 11, 1-11, May 5, 2015 ª2015 The Authors 7
were suspended in 200 ml of OpTmizer T Cell Expansion serum-free medium (SFM) (Life Technologies) and the cell suspensions were added to the upper chamber. Then, various concentrations of EPI-X4 or its derivatives in 600 ml T Cell Expansion SFM were added to the upper and lower chambers, and 10 nM of CXCL12 (R&D System) was added to the lower chamber. The cell-culture chambers were incubated for 150 min in a cell-culture incubator at 37 C.
After incubation, chambers were removed, 100 ml of supernatants was taken, and cells that had migrated into the lower compartment were either counted directly using a hemocytometer or analyzed using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). All values represent mean numbers of migrated cells relative to CXCL12-only treated cells from a triplicate experiment ± SD. Migration of human CD34+ cells was performed using frozen CD34+ cells from G-CSF-mobilized healthy volunteer donor apheresis products from the Institute for Transfusion Medicine (University of Ulm) and the Institute for Clinical Transfusion Medicine and Immunogenetics Ulm. Cells were maintained in CellGro SCGM medium (CellGenix) supplemented with 10% FCS, 100 ng/ml rhSCF, 20 ng/ml rhIL-3, and 25 ng/ml rhIL-6. Frozen cells were carefully thawed in 1/10 diluted 10% ACD-A buffer in PBS, and 1 3 10 5 /200 ml cells were placed into the upper chamber of transwell plates. Various concentrations of EPI-X4 were then added to the upper and lower chambers, and 10 nM CXCL12 was placed in the bottom well. After 3 hr, chemotaxis was measured using the CellTiter-Glo Luminescent Cell Viability Assay as described above. Values shown represent the mean percentage of migrated cells from one experiment performed in duplicate.
Cancer Cell Invasion
Invasion of cancer cells was assayed using a BioCoat Matrigel invasion chamber (BD) as recommended by the manufacturer. In brief, 5 3 10 4 DU145 cells (ATCC) were suspended in 300 ml of serum-free RPMI (GIBCO) containing 0.1% BSA (KPL) and then added to the upper chamber. Then, 700 ml serum-free medium with or without 100 nM CXCL12 and the indicated concentrations of EPI-X4 were added to each lower chamber. The chambers were incubated for 24 hr at 37 C in a humid atmosphere of 5% CO 2 /95% air.
The non-invading cells were removed from the upper surface of the membrane by scrubbing. Invaded cells toward the bottom of the membrane were quantified using the CellTiter-Glo Luminescent Cell Viability Assay kit as described above. Values shown are relative to those obtained for CXCL12 alone.
Progenitor Cell Mobilization in Mice
C57Bl/6J mice (Janvier) were housed in the conventional vivarium of the Goethe University Medical Center, Frankfurt, with food and water provided ad libitum. Mice received intraperitoneal (i.p.) injections of 200 ml of normal saline or normal saline containing 10 mg/ml EPI-X4. At the indicated times after injection, blood was drawn from the cheek pouch after careful skin disinfection. After hypotonic lysis of erythrocytes, leukocytes were incubated in duplicate in cytokine-replete, commercially available semisolid medium (3434, Stem Cell Technologies) under standard conditions. Colony-forming units in culture (CFU-C) were scored on day 7 as previously described (Bonig et al., 2006) . CFU-C scores were normalized to the blood volume incubated and are expressed as CFU-C/ml. were individually harvested at 1 hr post-injection, counted (the percentage of neutrophils in peripheral blood was determined using a differential blood cell counter [Hemavet; Drew Scientific]), combined, and competitively transplanted (660 ml blood equivalent) alongside 4 3 10 5 C57BL/6 CD45.1 BM cells into C57BL/6 Cd45.1 recipients as previously described (Ryan et al., 2010) . Recipient animals were subsequently analyzed for long-term multi-lineage chimerism in peripheral blood by flow cytometry.
Acute Allergic Airway Hypereosinophilia Mouse Model
On days 0, 1, and 2, mice were sensitized by i.p. injections of 50 mg OVA (A5503, Sigma-Aldrich) adsorbed on 2 mg of aluminum hydroxide (23918-6, Sigma-Aldrich) in saline. Mice were challenged by intranasal (i.n.) instillation of 10 mg OVA in 25 ml saline (12.5 ml/nostril) or saline alone for control mice on days 5, 6, and 7 under anesthesia (50 mg/kg ketamine and 3.3 mg/kg xylazine, i.p.). EPI-X4 or albumin fragment 409-423 in saline were administered i.p.
(16 mmol/kg) 2 hr before each OVA challenge. Bronchoalveolar lavage (BAL) and differential cell counts were performed 24 hr after the last OVA challenge as previously described (Reber et al., 2012) .
Cell Migration of Murine Pro-B Cells
Migration of murine BA/F3 pro-B cells was determined in a transwell assay as described in the Supplemental Experimental Procedures.
Degradation of EPI-X4 by LAP
In vitro degradation of EPI-X4 was performed by incubating 5 mg/ml EPI-X4 in undiluted fresh human plasma in the presence or absence of 0.05 U of LAP (L5006, Sigma-Aldrich) and 300 mM of LT (L8397, Sigma-Aldrich). Samples were incubated at 37 C for 1 hr and analyzed in an EPI-X4-specific sandwich ELISA.
Half-Life of EPI-X4 in Human Plasma
Fresh human plasma was spiked with 1 mg/ml EPI-X4 and incubated at 37 C and 5% CO 2 . At the indicated times, aliquots were taken and analyzed by an EPI-X4-specific sandwich ELISA.
HSA Structure
The 3D HSA structure was downloaded from the RCSB Protein Data Bank (PDB ID: 1H9Z), and pictures were generated using PyMOL software (DeLano Scientific LLC).
Proteolytic Digestion of HSA with Cathepsins
In vitro digestion of HSA was performed by incubating 400 mg/ml of HSA (126654, Calbiochem) in the presence or absence of 10 mg/ml of cathepsin D (C8696, Sigma-Aldrich) and cathepsin E (1294-AS-010; R&D Systems) or a buffer control in 50 ml of 0.2 M citrate buffer at the indicated pH. Samples were incubated at 37 C for 4 hr and then placed on ice to stop the digestion.
Samples were analyzed in an EPI-X4-specific sandwich ELISA.
De Novo Generation of EPI-X4 in Acidified Plasma
Fresh human plasma or PBS was acidified to pH 4 with 1 M of HCl. At the indicated time points, aliquots were taken and immediately stored at À80 C. The effect of a protease inhibitor (PI) cocktail (P8340, Sigma-Aldrich) on EPI-X4 generation was investigated by mixing 95% of acidified human plasma with 5% (v/v) of the protease inhibitor cocktail 1%, 5% (v/v) of DMSO (solvent), or 5% (v/v) of PBS. The effect of individual protease inhibitors was analyzed the same way. The final concentrations of individual PIs were 100 mM AEBSF (A8456, Sigma-Aldrich), 100 nM aprotinin (A1153, Sigma-Aldrich), 1 mM bestatin (B8385, Sigma), 10 mM E64 (E3132, Sigma-Aldrich), 10 mM leupeptin (L2884, Sigma-Aldrich), and 1 mM pepstatin A (P5318, Sigma-Aldrich). EPI-X4 concentrations were determined by EPI-X4-specific sandwich ELISA.
Detection of EPI-X4 in Sera from HIV-Infected Individuals
Plasma and serum from 102 HIV-infected individuals representing the full spectrum of viral load and disease progression were obtained from the Swiss HIV Cohort Study. Samples were collected while the individuals were treatment naive. See the Supplemental Experimental Procedures for details.
Detection of Urinary EPI-X4 and Correlation with the Severity of Chronic Kidney Disease
A total of 289 baseline urine samples from the Berlin Radio Contrast Media Study were analyzed (Heunisch et al., 2014) . Baseline urine analyzed in this study was obtained before contrast media exposure. Patients had chronic kidney disease (stages 1-4) and clinical signs of coronary artery disease. Patients were classified according to albumin excretion (urine albumin concentrations: 0-29.9 mg/l = normal, 30-299.9 mg/l = microalbuminuria; 300-6,000 mg/l = macroalbuminuria) and impairment of GFR (stage 1: 90-120 ml/min; stage 2 60-79.9 ml/min; stage 3: 30-59.9 ml/min; stage 4: 15-29.9 ml/min). Statistical analysis was done with SPSS 20 (IBM SPSS Statistics; IBM), and p < 0.05 was considered statistically significant.
Statistics
Statistical analysis of the results was done using GraphPad Prism 4.0 software.
Study Approval
All mouse experiments were performed in accordance with institutional and national guidelines and regulations, and were approved by the local commit- again, purified and tested (2 nd purification). After two more rounds of anti-HIV assays and 8 fractionation, fraction 30 obtained after the fourth purification step was subjected to mass 9 spectrometry, and its peptide sequence was determined by Edman degradation (see Figure 1A) . from HSA. Neutrophils were incubated with human serum albumin, and samples were taken at 7 0, 1, 5, 10, 20, 60, 120, and 180 min. Subsequently, the samples were chromatographed on a 8 reverse phase column, and collected fractions were analyzed by MALDI mass spectrometry. 9
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The Mr of 1,831.21, correlating with the theoretical average Mr 1,830.2 of EPI-X4, was 10 detected in the sample obtained after 10 min. EPI-X4 was identified by sequence analysis by 11 ESI-MSMS. Table S1 . Antiviral activity of EPI-X4 derivatives against X4 HIV NL4-3, Related to Figure  1   1 Other values give the minimum effective concentration that significantly crossed the vehicle 5 control threshold. 6 ↓ ↑= Direction of response. 7 NR = No response observed. 8 Table S3 . Long-distance NOEs between the residues of the hydrophobic core of EPI-X4, 1 
Supplemental Experimental Procedures 1
Cell viability and Cytotoxicity. TZM-bl cells or prestimulated PBMC were incubated with 2 increasing concentrations of peptides. Cell viability was determined using the CellTiter-Glo 3 Luminescent Cell Viability Assay (PROMEGA, G7571) as recommended by the manufacturer. 4
Values were derived from triplicate measurements. Vitality rates were calculated relative to ATP 5 levels in PBS (no peptide) containing cells (100%). Data were recorded using an Orion plate 6 luminometer 10 min after adding the reagent. The effect of Plerixafor (Calbiochem) and indicated 7 EPI-X4 derivatives on cell loss, nuclear size, nuclear morphology, cell membrane permeability, 8 mitochondrial membrane potential, mitochondrial mass and cytochrome c release was performed 9
by Cyprotex (Macclesfield, UK) using HepG2 cells as described (O'Brien et al., 2006) Internalization of EGFP-CXCR4 or EGFP-CXCR7. The human CXCR7 cDNA was cloned 1 in fusion with EGFP-cDNA into a modified pIRES Hyg 3 vector (Clonetech). HEK 293T cells 2 stably expressing EGFP-CXCR7 were generated by the calcium phosphate-DNA co-3 precipitation method. Internalization of receptors was carried out as described (Hachet-Haas et 4 al., 2008) . Briefly, HEK 293 cells expressing EGFP-CXCR4 or CXCR7 were pre-incubated for 5 30 min at 37°C with EPI-X4 (50 µM) or buffer. Thereafter, 100 nM of CXCL12 or CXCL11 6 were added, and 15 min later, the cell suspension was collected and labeled at the cell surface 7 with a monoclonal mouse anti-GFP (Roche Molecular Biochemicals; 1/100 dilution) as primary 8 antibody and a R-PE-conjugated AffiniPure F(ab′)2 fragment goat anti-mouse IgG 9 (Immunotech; 1/100) as secondary antibody. The proportion of chemokine receptors at the cell 10 surface was directly correlated to the ratio of the PE fluorescence intensity with chemokine to 11 that without chemokine. CXCR4 or CXCR7 staining was quantified by flow cytometric 12 analysis (10,000 cells per sample) on a cytometer (FACScalibur, Becton-Dickinson). Mean of 13 CXCR4 or CXCR7 fluorescence intensity was calculated using CELLQuest (Becton-14 Dickinson) software. 15 GPCR antagonist screen of EPI-X4. Antagonistic activity of EPI-X4 was analyzed by 16 DiscoveRx (Fremont, CA), using their proprietary PathHunter Biosensor Chemokine GPCR, 17 which quantifies GPCR activity using a β-arrestin recruitment-based β-galactosidase enzyme 18 complementation assay. Antagonistic activity was tested against a panel of 18 chemokine 19 receptors. EPI-X4 was used at a concentration of 1 mg/ml and co-incubated with receptor-specific 20 ligand at its EC80 concentration. % inhibition rates were calculated relative to basal and EC80 21 activity of relevant ligand alone. 22 and ii) by dividing these values by those obtained from the total cell input multiplied by 100. 12 NMR spectroscopy of EPI-X4. For acquisition of NMR spectra, a 1 mM solution of EPI-X4 13 was prepared in 10 mM Na-phosphate in H2O/D2O 10:1, adjusted to a final pH of 7.0 with HCl. 14 TOCSY and NOESY 1 H-NMR spectra were recorded at 800 MHz, 600 MHz and 500 MHz on 15
Bruker spectrometers. The spectra acquired in the 800 MHz equipment were used due to their 16 better quality. Spectra were referenced to external TSP, and they were recorded using the States-17 TPPI method incorporating the watergate 3-9-19 pulse sequence for water suppression (Jeener 18 et al., 1979) . In general, 256 equally spaced evolution-time period t1 values were acquired, 19 averaging 16 transients of 2048 points. Time-domain data matrices were all zero-filled to 4K 20 in both dimensions, thereby yielding a digital resolution of 3.41 Hz/pt. Prior to Fourier 21 transformation, a Lorentz-Gauss window with different parameters was applied to both the t1 22 and t2 dimensions for all the experiments. NOESY spectra (Griesinger et al., 1988) were 23 obtained with mixing times (0.30 s) and TOCSY experiments (Braunschweiler and Ernst, 1983; 24 Rucker and Shaka, 2006) were recorded using 0.060 s DIPSI2 mixing pulses. Both NOESY 25
and TOCSY experiments were performed at 25°C. 26 NOESY cross-peak assignment and structure calculation of EPI-X4. The 1 H chemical shift 27 dispersion in NMR spectra allowed a straightforward non-ambiguous assignment of all the NH-1 and CH-alpha resonances, as well as the vast majority of side-chain protons (97.7%), using 2 standard methodology, combining TOCSY and NOESY spectroscopy. The sequential 3 backbone connectivity's were established by following the αCHi-NHi+1 and the NHi-NHi+1 4
NOEs. Peak lists for the NOESY spectra recorded with a 0.30 s mixing time were generated by 5 interactive peak picking using the XEASY software (Bartels et al., 1995) . NOESY cross-peak 6 volumes were determined by the automated peak integration routine, peakin implemented in 7 XEASY. The three-dimensional structure of EPI-X4 was determined using the standard 8 protocol of combined automated NOE assignment and structure calculation of the CYANA 9
program (Herrmann et al., 2002; Güntert, 2003 Güntert, , 2004 . The 20 best conformers selected showed 10 low CYANA target function values (with mean target function: 0.056). 400 (98.2%) NOESY 11 cross-peaks of the 407 submitted to CYANA were unambiguously assigned by the program. 12
Seven cycles of combined automated NOESY assignment and structure calculations were 13 followed by a final structure calculation. The structure calculation commenced in each cycle 14 from 100 randomized conformers and the standard simulated annealing schedule was used. The 15 20 conformers with the lowest final CYANA target function values were retained for analysis 16 and passed to the next cycle. Constraint combination was applied in the first two cycles to all 17 NOE distance restraints, spanning at least three residues, in order to minimize structural 18 distortion by erroneous distance restraints. The covalent parameters of Engh and Huber were 19 used (Engh and Huber, 1991) . Restraints that involved degenerate groups of protons (e.g. 20 methyls), accidentally degenerated to methylenes, and equivalent aromatic ring protons were 21 expanded into ambiguous distance restraints between all the corresponding pairs of hydrogen 22 atoms. Non-degenerate diastereotopic pairs were periodically swapped for minimal target 23 function values during simulated annealing in cycles 1-7. Weak restraints on φ/ torsion angle 24 pairs and on side-chain torsion angles between tetrahedral carbon atoms were temporarily 25 applied during the high-temperature and cooling phases of the simulated annealing schedule in 26 order to favor the permitted regions of the Ramachandran plot and staggered rotamer positions, 27 respectively. The list of upper distance bonds for the final structural calculation is exclusively 1 comprised of unambiguously assigned upper distance bonds and does not require the possible 2 swapping of diastereotopic pairs. 3
Structure of EPI-X4. The 20 conformers with the lowest final CYANA target function values 4 bundle tightly ( Figure 5A ) and, consequently, show a remarkably low RMSD for a peptide of 5 16 residues (mean global backbone RMSD of 1.73 for the full length polypeptide, 1.26 if 6 residues 1-14 are exclusively considered (Koradi et al., 1996) , which allows a significant mean 7 three-dimensional structure of EPI-X4 to be computed, afterwards refined using the AMBER 9 8 package (Case et al., 2006) . As shown in table S3, there are strong long-distance NOEs between 9 the protons of the methyl groups of the N-terminal Leu and those of the ring of Pro9, which 10 reveals the existence of a strong hydrophobic interaction between those two chemical groups. 11
To this interaction the Tyr4 ring is added, the protons of which participate in three medium/large 12 range NOEs with those of the methyl groups of Leu1 (average distance, 4.6 Å), and in six 13 significant and clearly detectable weak NOEs with those of the Pro9 ring (average distance, 14 5.33 Å). This hydrophobic nucleus causes the backbone of the Leu1-Pro9 stretch to adopt a sort 15 of ring structure ( Figure 5B ) that orients the lateral chains of Arg3, Lys6, Lys7 plus the N-16 terminus of Leu1 towards one of its faces, which consequently shows a highly positive charge 17 ( Figure 5C ). The structural relevance of this ring is clearly underscored by the dramatic decrease 18 in EPI-X4 activity when Leu1 is eliminated (Table S1 ). The other face of the ring is shielded 19 from the solvent by the rest of EPI-X4, mainly by the stretch Gln10-Pro14 which shows strong 20 hydrophobic interactions with this later face, as shown by the high number of strong NOEs 21 between the protons of the methyl group of the Thr5 lateral chain with those of the ring of Pro14 22 and side-chain protons of Thr13 and (Table S3 ). Tyr4 weakly, but clearly, also interacts with 23 Thr13, bridging this last hydrophobic nucleus with the one described above ( Figure 5B and 24 Table S3 ). The clustering of such a high density of charges at one face of EPI-X4 involves a 25 high entropic cost that is obviously exceedingly compensated, as suggested by the strong 26 bundling of conformers resulting from the CYANA calculations by the shielding from thesolvent of the two hydrophobic nuclei described in previous paragraphs. Thus, the EPI-X4 1 structure is a metastable state in which two forces of opposite directions reciprocally 2 counterpoise, with obvious predominance of one of them. Consequently, this structure 3 constitutes a sort of loaded spring that can abruptly lead to its deep disassembly by small 4 alterations of the elements involved in the balance (vg. elimination of Leu1; Table S1 ). 5
Binding model of the natural ligands CXCL12, EPI-X4 and the V3 loop of gp120 to 6 CXCR4. The atomic structure of the cell membrane protein to which EPI-X4 binds, the G 7 protein-coupled chemokine receptor CXCR4, has been recently published, bound to two 8 antagonists (Wu et al., 2010) . A representation of the structure of CXCR4 bound to the cyclic 9 peptide CVX15 (PDB entry code: 3OE0) was used to model the binding process of EPI-X4. 10
The electrostatic potential of the CXCR4 surface facing the extracellular space is shown in 11 Figure S3 . In this Figure, CVX15 has been detached from the complex to show the deep 12 negatively charged well where the ligands bind. Residues assigned to extracellular loops 2 and 13 3 in the traditional three-dimensional models of CXCR4 are mainly responsible for the creation 14 of this negatively charged well. This well is probably less defined in the free form than it 15 appears in the figure, as crystallization of CXCR4 seemed unfeasible in the absence of 16 antagonists, and slight differences were observed between the structures of the protein bound 17 to the two different antagonists used for crystallization. Consequently, it seems that there is a 18 certain degree of induced fitting in CXCR4 when the complex forms with its ligands. 19
Conservation score of EPI-X4 in serum albumins of various species. (http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/valdar/scorecons_server.pl).
The 21
